Research graph
References from Abnormal serum immunofixation patterns are common after BCMA CAR-T in multiple myeloma and are preceded by immune events. Local targets link to admitted publications; unresolved targets remain external evidence.
Clinical characteristics and prognostic significance of immunoglobulin isotype switch in patients with multiple myeloma
10.1016/j.cpt.2022.11.002 · 2023 · External reference
Immunoglobulin isotypes in multiple myeloma: laboratory correlates and prognostic implications in total therapy protocols
10.1111/j.1365-2141.2008.07547.x · 2009 · External reference
Oligoclonal and monoclonal bands after single autologous stem cell transplant in patients with multiple myeloma: impact on overall survival and progression-free survival
10.3109/10428194.2013.873537 · 2014 · External reference
Atypical serum immunofixation pattern (ASIP) development during induction therapy with BiRD for newly diagnosed multiple myeloma correlates with a high rate of complete remission
10.1182/blood.v110.11.2737.2737 · 2007 · External reference
Atypical serum immunofixation patterns frequently emerge in immunomodulatory therapy and are associated with a high degree of response in multiple myeloma
10.1111/j.1365-2141.2008.07374.x · 2008 · External reference
For survival, the emergence of oligoclonal bands after multiple myeloma treatment is less important than achieving complete remission
10.1016/j.bjhh.2017.05.010 · 2017 · External reference
Oligoclonal bands in patients with multiple myeloma: its emergence per se could not be translated to improved survival
10.1111/cas.12527 · 2014 · External reference
Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study
10.1016/s0140-6736(21)00933-8 · 2021 · External reference
Idecabtagene vicleucel in relapsed and refractory multiple myeloma
10.1056/nejmoa2024850 · 2021 · External reference
Cilta-cel or standard care in lenalidomide-refractory multiple myeloma
10.1056/nejmoa2303379 · 2023 · External reference
Hypogammaglobulinemia after chimeric antigen receptor (CAR) T-cell therapy: characteristics, management, and future directions
10.1016/j.jaip.2021.10.037 · 2022 · External reference
Managing hypogammaglobulinemia in patients treated with CAR-T-cell therapy: key points for clinicians
10.1080/17474086.2022.2063833 · 2022 · External reference
Clonal dysregulation of the antibody response to tetanus-toxoid after bone marrow transplantation
10.1182/blood.v84.12.4374.bloodjournal84124374 · 1994 · External reference
Multiple myeloma related cells in patients undergoing autologous peripheral blood stem cell transplantation
10.1046/j.1365-2141.1999.01233.x · 1999 · External reference
Absolute lymphocyte count after BCMA CAR-T therapy is a predictor of response and outcomes in relapsed multiple myeloma
10.1182/bloodadvances.2023012470 · 2024 · External reference
Serum immunoglobulin changes in multiple myeloma patients treated with CAR T-cell therapy
10.3390/cimb47080640 · 2025 · External reference
The incidence and clinical significance of monoclonal and oligoclonal protein bands in multiple myeloma patients after BCAM-CAR-T cell therapy: a retrospective study based on LEGEND-2
10.1002/hem3.70054 · 2024 · External reference
Immunoglobulin isotype switch after anti-BCMA CAR T-cell therapy for relapsed or refractory multiple myeloma
10.1182/bloodadvances.2021005814 · 2022 · External reference
Abnormal serum fixation patterns are a common event following BCMA CAR-T in relapsed refractory multiple myeloma and are often preceded by immunological events [abstract]
10.1016/s2152-2650(24)01957-8 · 2024 · External reference
Abnormal serum fixation patterns are a common event following BCMA CAR-T therapy in relapsed refractory multiple myeloma and are often preceded by immunological events [abstract]
10.1182/blood-2024-210365 · 2024 · External reference
Unresolved reference
2025 · External reference
